syed arif ahmad, md - University of Cincinnati Department of Surgery

Syed A. Ahmad, MD 6
3. Principal Investigator: Selective COX-2 Inhibition As Adjuvant Treatment after
Resection of Colorectal Liver Metastases
4. Principal Investigator: A Phase II Study Evaluating the Role of Epidermal
Growth Factor Receptor Inhibition Utilizing ZD1849 (Iressa) in Combination with
Gemcitabine (Gemzar) as Adjuvant Treatment for Pancreatic Cancer.
5. Principal Investigator: FOLFIRINOX followed by chemoradiation for
Borderline Resectable Pancreas Cancer. (SWOG/ Alliance/ ECOG Study)
Grants:
Principle Investigator
2000 American Cancer Society Institutional Grant. Selective COX-2 Inhibition
As Adjuvant Treatment after Resection of Colorectal Liver Metastases,
$20,000. (10% Effort)
2003 American Cancer Society State Grant. A Phase II Study Evaluating the
Role of Epidermal Growth Factor Receptor Inhibition Utilizing ZD1849
(Iressa) in Combination with Gemcitabine (Gemzar) as Adjuvant Treatment
for Pancreatic Cancer. $20,000. (10% Effort)
Pharmaceutical Supported Trials:
Principle Investigator
2001-Pharmacia Oncology. Selective COX-2 Inhibition As Adjuvant
Treatment after Resection of Colorectal Liver Metastases.
2003-Astra-Zeneca. A Phase II Study Evaluating the Role of Epidermal Growth Factor
Receptor Inhibition Utilizing ZD1849 (Iressa) in Combination with Gemcitabine (Gemzar)
as Adjuvant Treatment for Pancreatic Cancer. (10% Effort)
Appointments:
1. Junior Faculty Associate, The University of Texas M. D. Anderson Cancer Center,
Houston, Texas.
2. Assistant Professor of Surgery, The University of Cincinnati School of Medicine,
Cincinnati, Ohio.
3. Director of Pancreatic Disease Center, The University of Cincinnati School of
Medicine, Cincinnati, Ohio (2007-Present)